Please login to the form below

Not currently logged in
Email:
Password:

EASD: Study supports early use of Victoza

Novo Nordisk's GLP-1 analogue Victoza has greater benefit ifused early in the treatment of type 2 diabetes according to a study presentedat the European Association for the Study of Diabetes meeting

Novo Nordisk's GLP-1 analogue Victoza (liraglutide) has greater benefit if used early in the treatment of type 2 diabetes according to a study presented at the European Association for the Study of Diabetes (EASD) meeting in Lisbon, Portugal.

When used early in the treatment process, 72 per cent of patients treated with Victoza were able to achieve glycaemic control compared to 49 per cent who were treated late on. Glycaemic control was defined as the EASD target of HbA1c levels of less than 7 per cent.

Both results were significantly higher than compared to comparator groups in the trial: patients who had not received treatment before or previously only one oral anti-diabetic drug.

A separate study also presented at EASD showed that patients who switched from oral therapy with sitagliptin (marketed as Januvia by Merck) to once-daily injectable therapy with Victoza had an increase in overall treatment satisfaction based on the Diabetes Treatment Satisfaction Questionnaire at 52 and 78 weeks.

Study investigator, Professor Eduard Montanya from the Medical School of the University of Barcelona, Spain, said the increased satisfaction was partly due to greater weight loss associated with Victoza.

15th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics